These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2008787)

  • 1. Therapeutic monitoring and pharmacokinetic evaluation of procainamide in neonates.
    Bryson SM; Leson CL; Irwin DB; Trope AE; Hosking MC
    DICP; 1991 Jan; 25(1):68-71. PubMed ID: 2008787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
    Moffett BS; Cannon BC; Friedman RA; Kertesz NJ
    Pharmacotherapy; 2006 Dec; 26(12):1687-93. PubMed ID: 17125432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration.
    Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG
    J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy.
    Tisdale JE; Rudis MI; Padhi ID; Borzak S; Svensson CK; Webb CR; Acciaioli J; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1996 Jan; 36(1):35-41. PubMed ID: 8932541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.
    Bauer LA; Black DJ; Lill JS; Garrison J; Raisys VA; Hooton TM
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1649-51. PubMed ID: 15793163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
    Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
    J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity.
    Low CL; Phelps KR; Bailie GR
    Nephrol Dial Transplant; 1996 May; 11(5):881-4. PubMed ID: 8671917
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of an open-loop, computer-based infusion system designed to achieve a series of constant, targeted plasma procainamide concentrations in patients undergoing electrophysiologic testing.
    Coyle JD; Carnes CA; Schaal SF
    Pharmacotherapy; 1997; 17(3):445-56. PubMed ID: 9165549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amiodarone on the disposition of procainamide in the rat.
    Liu LL; Knowlton PW; Svensson CK
    J Pharm Sci; 1988 Aug; 77(8):662-5. PubMed ID: 3210153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of sematilide in renal failure.
    Shi J; Ripley E; Gehr TW; Sica DA; Dandekar KA; Hinderling PH
    J Clin Pharmacol; 1996 Feb; 36(2):131-43. PubMed ID: 8852389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procainamide elimination kinetics in pediatric patients.
    Singh S; Gelband H; Mehta AV; Kessler K; Casta A; Pickoff AS
    Clin Pharmacol Ther; 1982 Nov; 32(5):607-11. PubMed ID: 7128001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.